Image For Activity Cover
Moving Towards Personalized Therapy in Endometrial Cancer
Description & Faculty
Treatment options for patients with advanced or recurrent endometrial cancers are rapidly evolving. Dr. Vicky Makker shares recent report from ASCO 2024 on Selinexor, a novel oral maintenance therapy for patients with TP53 wild type advanced or recurrent endometrial cancer. 


Vicky Makker, MD
Section Head, Endometrial Cancer Program
Director, Hematology-Medical Oncology Fellowship Training Program
Memorial Sloan Kettering Cancer Center 
USA

Floor Backes, MD
Moderator
Director of Clinical Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA

Supported in part by
Summary
Availability: On-Demand
Cost: FREE
Recommended
Contact education@igcs.org for assistance.
Powered By